Evidence map›Paper›PMID 27487132›Full record

ArticleOncotarget2016

YMO1 suppresses invasion and metastasis by inhibiting RhoC signaling and predicts favorable prognosis in hepatocellular carcinoma.

Rui-Min Chang, Lei Pei, Feng Fang, Jiang-Feng Xu, Hao Yang, Chao-Hui Zuo, Jian-Hua Zhou, Geng-Qiu Luo, Lian-Yue Yang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rui-Min ChangLiver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Lei PeiLiver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Feng FangLiver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Jiang-Feng XuLiver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Hao YangLiver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Chao-Hui ZuoDepartment of Abdominal Surgical Oncology, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Jian-Hua ZhouDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Geng-Qiu LuoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha 410008, China.
Lian-Yue YangLiver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Central South University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have shown that 4.1 proteins, which are deregulated in many cancers, contribute to cell adhesion and motility. Yurt/Mosaic eyes-like 1 (YMO1) is a member of 4.1 protein family but it is unclear whether YMO1 plays a role in tumor invasion. This study aimed to investigate the effects of YMO1 on hepatocellular carcinoma (HCC) and attempted to elucidate the underlying molecular mechanisms. YMO1 expression in HCC tissues and its correlation with clinicopathological features and postoperative prognosis was analyzed. The results showed that YMO1 was down-regulated in the highly metastatic HCC cell line and in human tumor tissues. Underexpression of YMO1 indicated poor prognosis of HCC patients. Restoration of YMO1 expression caused a significant decrease in cell migration and invasiveness in vitro. In vivo study showed that YMO1 reduced liver tumor invasion and metastasis in xenograft mice. YMO1 directly inhibited RhoC activation. YMO1 expression in HCC was regulated by PAX5. Analysis of YMO1 expression levels in human HCC patients revealed a significant correlation of YMO1 expression with PAX5 and RhoC. Our findings revealed that YMO1 predicts favorable prognosis and the data suggest that YMO1 suppresses tumor invasion and metastasis by inhibiting RhoC activity.

Indexed as

AdultAgedAnimalsCarcinoma, HepatocellularCell Line, TumorCell MovementFemaleHumansLiver NeoplasmsMaleMembrane ProteinsMiceMiddle AgedNeoplasm InvasivenessPAX5 Transcription FactorPrognosisEPB41L5 protein, humanMembrane ProteinsPAX5 protein, humanPAX5 Transcription Factorrho-Associated KinasesrhoC GTP-Binding ProteinRHOC protein, humanROCK1 protein, humanhepatocellular carcinomametastasisPAX5RhoCYMO1

Identifiers

PMID27487132
PMCPMC5342438
OpenAlexW2476217916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.